Prime Medicine $191M Cash Runway, Targets Wilson Disease and AATD INDs
Prime Medicine ended 2025 with $191.4M in cash and investments, extending its runway into 2027, after a $201.1M net loss and $160.6M in R&D spending. The company plans IND/CTA filings for Wilson Disease in 1H 2026 and AATD by mid-2026, with initial clinical data expected in 2027.
1. Full Year 2025 Financial Results
Prime Medicine recorded a net loss of $201.1M for 2025 compared with $195.9M a year earlier, driven by R&D expenses of $160.6M and G&A costs of $52.3M. The company ended the year with $191.4M in cash, equivalents, investments and restricted cash, supporting operations into 2027.
2. Pipeline and Regulatory Milestones
The company plans to file an IND for its Wilson Disease program targeting the H1069Q mutation in the first half of 2026, and to submit an IND/CTA for its AATD franchise by mid-2026. Initial clinical data for both in vivo liver-focused programs are expected in 2027, with preclinical proof-of-concept for the cystic fibrosis program anticipated in 2026.
3. PM359 CGD Program and BLA Strategy
Prompted by breakthrough Phase 1/2 data for PM359 in chronic granulomatous disease, Prime Medicine is engaged with the FDA toward final alignment and intends to submit a Biologics License Application. PM359’s rapid engraftment and durable restoration of NADPH oxidase activity support a potential accelerated approval path.